Moderna’s Dual Covid-Flu Vaccine Poised for EMA Approval on Positive CHMP Take

Why It Matters

A combined vaccine could streamline immunisation programs and boost uptake, while Moderna’s strategic shift signals a broader industry move toward diversified, high‑margin therapeutics.

Key Takeaways

• EMA backs Moderna's Covid‑flu combo vaccine.
• mCombriax outperformed Sanofi flu + Spikevax in Phase III.
• Approval could launch first global Covid‑flu combination.
• US FDA delays highlight divergent regulatory paths.
• Moderna shifts focus to oncology for long‑term growth.

Pulse Analysis

The European Medicines Agency’s positive opinion on Moderna’s mCombriax marks a watershed moment for combination immunizations. By merging a mRNA‑based COVID‑19 booster with a quadrivalent influenza component, the candidate promises to streamline seasonal vaccination campaigns and reduce administration costs. The Phase III trial demonstrated superior antibody titers against both SARS‑CoV‑2 and three flu strains compared with a mixed regimen of Sanofi’s high‑dose flu shot and Spikevax. If the EMA grants marketing authorisation, mCombriax could become the first commercially available Covid‑flu cocktail, setting a new benchmark for multi‑pathogen vaccines.

\nRegulatory pathways, however, remain uneven. In the United States, the FDA has stalled Moderna’s flu‑only candidate mRNA‑1010 and demanded additional efficacy data before green‑lighting the combination product, reflecting heightened scrutiny of trial designs post‑pandemic. The EMA’s more favorable stance underscores Europe’s appetite for integrated vaccines, yet it also highlights the risk of divergent market entry timelines. Companies must now navigate parallel submissions, balancing data packages to satisfy distinct agency expectations while preserving commercial momentum across both continents. \nAgainst this backdrop, Moderna is rebalancing its portfolio toward oncology and rare diseases, sectors that promise higher margins and less regulatory volatility.

The company reported an $826 million net loss in Q4 2025, driven by waning COVID‑19 sales, prompting CEO Stéphane Bancel to prioritize late‑stage cancer trials slated for 2026. Analysts at William Blair view the oncology pipeline as a credible long‑term growth engine, especially as multiple mRNA‑based therapeutics advance toward approval. Successful oncology readouts could diversify revenue streams by 2027, reducing reliance on COVID‑19 sales. If the oncology candidates achieve their projected endpoints, Moderna could see revenue diversification within the next three years, redefining its market identity.